Thymalin is a polypeptide complex extracted from calf thymus tissue, developed within the same Russian short-peptide bioregulator research program described in bioregulator peptides explained. It differs from most of the other peptides in that program in an important structural way: where compounds like Pinealon and Vilon are single synthetic sequences of two to four amino acids, Thymalin is a mixture of low-molecular-weight peptides purified from thymus tissue rather than one defined chemical entity. That difference shapes how it has been studied. Published work on Thymalin spans decades and includes both animal-tumor and cell-differentiation experiments and, more recently, observational reports published during the COVID-19 pandemic, when interest in thymus-directed immune peptides increased. This article looks at what those specific studies measured rather than repeating the general history of the bioregulator peptide family.
| Attribute | Detail |
|---|---|
| Name | Thymalin, thymic polypeptide complex |
| Composition | Mixture of low-molecular-weight peptides isolated from calf thymus, including KE and EW dipeptide components |
| Class | Tissue-extracted immune bioregulator complex |
| What studies examine | T-lymphocyte and hematopoietic stem cell differentiation markers, tumor growth in rodent models, cytokine production, gene expression relevant to viral infection response |
| Model systems used | Human hematopoietic stem cell cultures, rats with transplanted sarcoma, peripheral blood cell cultures, observational studies in hospitalized patients |
| Form supplied | Lyophilized powder, research use only |
What is Thymalin made of, and how does that differ from the synthetic short peptides in the same family?
Thymalin was developed by isolating and purifying a set of peptides directly from thymus tissue rather than by synthesizing a single defined amino acid sequence. Later molecular work identified two of its component dipeptides as Lys-Glu, abbreviated KE, and Glu-Trp, abbreviated EW, and examined how each contributes to the complex's overall activity on gene expression relevant to viral infection response, rather than treating Thymalin as a single molecule with one mechanism (Linkova et al., 2023). For background on how Thymalin's role fits alongside the synthetic tetra- and tripeptides in the wider bioregulator program, see bioregulator peptides explained; for a comparison with a single 28-amino-acid thymic peptide studied in a related but structurally distinct immune-research context, see what is Thymosin Alpha-1.
What has research examined in human hematopoietic stem cell cultures?
A 2020 study examined Thymalin's effect on differentiation of human hematopoietic stem cells in culture, reporting that it reduced expression of CD44 and CD117, markers associated with stem cells and an intermediate stage of differentiation, while increasing expression of CD28, a marker of mature T lymphocytes, roughly seven-fold in the cultures tested. The authors proposed that this shift indirectly reflects a role for Thymalin in stimulating differentiation of these progenitor cells toward mature T lymphocytes, a population reported to be reduced in blood samples from patients with severe COVID-19 in other published work (Khavinson et al., 2020).
What has research examined in animal tumor models?
Experiments in albino outbred male rats with transplanted sarcoma 45 examined Thymalin administered at doses below its typical therapeutic range, reporting tumor growth arrest and regression in more than half of the treated animals and substantial growth suppression in the remainder. The same study documented microstructural changes in the thymus of treated rats, including increased lymphoproliferative activity and higher counts of tissue basophils and plasmocytes in thymus lobules, and linked tumor regression to the development of specific physiological stress-adaptation states in the animals (Zhukova et al., 2018).
What has comparative immunomodulator research examined?
A comparative study evaluated Thymalin's immunomodulatory activity against a peptide preparation derived from squid optical ganglia, testing both in animals and in cultured human peripheral blood cells. Thymalin's effects on humoral and cellular immune responses and on neutrophil phagocytic activity served as the reference standard the comparator peptide was measured against, and both preparations increased production of the pro-inflammatory cytokines TNF-alpha and IL-1 as well as the anti-inflammatory cytokine IL-10 in cultured blood cells (Kuznetsova et al., 2013).
What has research examined in reproductive-organ inflammation and chronobiology?
A study in women of reproductive age with chronic salpingitis and oophoritis examined individual diurnal variation in how blood lymphocyte succinate dehydrogenase activity responded to Thymalin or a comparator drug, ridostin, when the drugs were added to lymphocyte cultures. The authors reported that an in vitro lymphocyte enzymatic response to the preparation tracked with the immunological parameters they measured, and proposed the in vitro assay as a way to characterize responsiveness at the cellular level., 2015).
What has research examined during the COVID-19 pandemic?
A 2021 paper reviewed results and outlined further directions for using Thymalin, described by the authors as an activator of hematopoietic stem cell differentiation, within complex therapy protocols for hospitalized COVID-19 patients, building on the mechanistic hematopoietic stem cell findings summarized above and on broader clinical observations of T-lymphocyte depletion in severe disease (Khavinson et al., 2021). As with the sarcoma and stem-cell work, this line of research treats Thymalin as an immune-system modulator under laboratory and clinical-observational study, not as an established standard-of-care treatment.
Handling notes
Thymalin is supplied as a lyophilized powder intended for research use. Because it is a peptide complex rather than a single defined molecule, lot-to-lot composition can vary more than it does for a single synthetic sequence, which makes checking the certificate of analysis for each lot particularly important; see peptide research glossary for definitions of the identity and purity terms that appear on that document. Reconstitute using standard bench technique and store per the certificate of analysis. Lot-specific specifications for research-grade Thymalin are posted on our Thymalin lot page.
Frequently asked questions
Is Thymalin a single peptide or a mixture?
Thymalin is a polypeptide complex purified from thymus tissue, not a single synthetic sequence. Molecular studies have identified component dipeptides including Lys-Glu and Glu-Trp within the complex.
What cell types have published studies examined for Thymalin?
Published work has examined human hematopoietic stem cells, cultured human peripheral blood cells, thymus tissue from rats with transplanted tumors, and blood lymphocytes from human patients in observational studies.
Has Thymalin been studied in tumor-bearing animals?
Yes. A rat sarcoma 45 model reported tumor growth arrest and regression at doses lower than Thymalin's typical therapeutic range, along with microstructural changes in the thymus of treated animals.
How does Thymalin differ from Thymosin Alpha-1?
Thymalin is a peptide complex isolated from thymus tissue, while Thymosin Alpha-1 is a single, well-defined 28-amino-acid peptide. Both have been studied in immune-research contexts but come from different research traditions and different peptide categories; see what is Thymosin Alpha-1 for that peptide's own literature.
Has Thymalin been studied in the context of COVID-19?
Yes, in laboratory studies of hematopoietic stem cell differentiation markers and in reviews discussing its potential role within complex therapy approaches during the pandemic. This reflects published research interest, not a claim of clinical efficacy.
How is Thymalin supplied for laboratory use?
As a lyophilized powder intended for research use only, sold by lot with an accompanying certificate of analysis.
References
- Khavinson VK, Linkova NS, Kvetnoy IM, Polyakova VO, Drobintseva AO, Kvetnaia TV, Ivko OM. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bull Exp Biol Med. 2020;170(1):118-122. PubMed 33237528.
- Linkova N, Khavinson V, Diatlova A, et al. The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. Int J Mol Sci. 2023;24(17):13720. PubMed 37686182.
- Zhukova GV, Schikhlyarova AI, Barteneva TA, Shevchenko AN, Zakharyuta FM. Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo. Bull Exp Biol Med. 2018;165(1):80-83. PubMed 29797130.
- Kuznetsova TA, Besednova NN, Zaporozhets TS, Smolina TP, Kazha AK, Ivanushko LA. Comparative study of immunomodulatory activity of peptides, tinrostim and thymalin. Antibiot Khimioter. 2013;58(11-12):8-12. PubMed 24734422.
- Litvinenko GI, Shurlygina AV, Dergacheva TI, Mel'nikova EV, Trufakin VA. Chrono- and Immunocorrection of Inflammatory Disorders of Internal Reproductive Organs in Women of Reproductive Age. Bull Exp Biol Med. 2015;159(1):62-65. PubMed 26033592.
- Khavinson VK, Kuznik BI, Trofimova SV, et al. Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19. Stem Cell Rev Rep. 2021;17(1):285-290. PubMed 33575961.
Research use only. Homegrown Peptides products are for laboratory research and are not for human or animal use. Nothing in this article is medical advice.
